Temel B, Orenay OM, Yigit D, Kaymak D, Karaosmanoglu N, Eksioglu HM. Evaluation of Dermatology Life Quality Index, Depression-Anxiety-Stress Scores of Patients with Genital Dermatoses.
Indian J Dermatol 2023;
68:399-404. [PMID:
37822383 PMCID:
PMC10564216 DOI:
10.4103/ijd.ijd_424_23]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/13/2023] Open
Abstract
Background
Genital dermatoses contain a group of diseases that affect the skin of the genital area. Genital dermatoses are classified as venereal and nonvenereal. They can affect a patient's life quality and can cause depression, anxiety and stress.
Aims
This study aimed to evaluate and compare the quality of life index, depression, stress and anxiety in patients with genital dermatoses.
Materials and Methods
Patients admitted to the dermatology outpatient clinic with genital skin complaints between October 2020 and March 2021 were included. A questionnaire including demographic information, a 10-item dermatology life quality index (DLQI) and a 21-item depression anxiety stress score (DASS-21) was filled out by the patients and was calculated.
Results
A total of 103 patients were included in this study. Seventy-seven (74.8%) were male and 26 (25.2%) were female. A total of 48.5% (n = 50) patients had venereal genital dermatoses, and 51.5% (n = 53) of the patients had nonvenereal genital dermatoses. In the venereal diseases, syphilis had the highest DLQI, depression, anxiety and stress score while in the nonvenereal diseases, scabies had the highest DLQI, depression, anxiety and stress score. In the nonvenereal group, the mean DLQI score, depression, anxiety and stress scores were statistically significantly higher than the venereal genital dermatoses group (P < 0.01, P = 0.04, P = 0.03 and P = 0.02).
Conclusion
The quality of life of patients with genital dermatoses is often poor, with significant levels of depression, anxiety and stress. We believe that screening these patients with DLQI and DASS-21 scores at their first admission and follow-up will benefit dermatologists and patients.
Collapse